MNK Mallinckrodt plc

21.49
+0.97  (+5%)
Previous Close 20.52
Open 21.03
Price To Book 0.27
Market Cap 1790401528
Shares 83,313,240
Volume 1,538,812
Short Ratio 13.4
Av. Daily Volume 1,806,692

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be completed 2H 2019.
Terlipressin
Hepatorenal syndrome (HRS) Type 1
CRL issued August 22, 2018.
Stannsoporfin
Jaundice
Phase 2 data due 1H 2020.
H.P. Acthar Gel
Amyotrophic Lateral Sclerosis
Phase 3 enrolment to stop following interim analysis February 20, 2019.
UVADEX (methoxsalen) and Therakos
Acute Graft Versus Host Disease
Phase 2 commencement of enrollment announced August 2, 2018.
MNK-1411
Duchenne Muscular Dystrophy
Approved April 30, 2015.
RAPLIXA
Hemostasis
Phase 3 data due 2H 2019.
StrataGraft skin tissue
Deep partial thickness severe burns - skin defects
Phase 2 data due 2H 2019.
StrataGraft skin tissue
Full thickness severe burns - skin defects
Phase 3 trial did not show a statistically significant separation from placebo.
VTS-270
Niemann-Pick Disease
Phase 3 commencement of enrolment announced December 21, 2018. Interim analysis 4Q 2019 with completion due 2020.
Inhaled Xenon Gas Therapy
Post-cardiac arrest
CRL issued December 12, 2018.
MNK-812
Pain
Phase 3 data due early 2019.
CPP-1X/sulindac
Familial Adenomatous Polyposis (FAP)

Latest News

  1. What's in the Cards for Perrigo (PRGO) This Earnings Season?
  2. Zacks.com featured highlights include: Mallinckrodt, Dell, American Axle, Daqo and General Motors
  3. Another Round of Slight Gains Amid Choppy Session
  4. 6 Low Price-to-Book Stocks for Value Investors
  5. Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
  6. Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
  7. Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
  8. Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
  9. What's in the Cards for Amarin (AMRN) This Earnings Season?
  10. What's in the Cards for Bausch Health (BHC) Q4 Earnings?
  11. MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
  12. Mallinckrodt To Present At Barclays Global Healthcare Conference
  13. Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
  14. Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
  15. Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
  16. See what the IHS Markit Score report has to say about Mallinckrodt Plc.
  17. Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
  18. 6 Low Price-to-Book Value Stocks to Buy in February
  19. Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again
  20. Mallinckrodt Provides Update on Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis (RA)